| |
Number of patients with response/total number of patients, n/N (%) |
| Visit Week |
IR-XR post48a |
IR-IR post48b |
XR-XR post48c |
Total |
| Week 48 |
125/130 (96.2) |
11/12 (91.7) |
268/276 (97.1) |
404/418 (96.7) |
| Week 60 |
122/130 (93.8) |
9/12 (75.0) |
253/274 (92.3) |
384/416 (92.3) |
| Week 72 |
124/130 (95.4) |
9/9 (100) |
265/271 (97.8) |
398/410 (97.1) |
| Week 84 |
118/125(94.4) |
7/8 (87.5) |
244/268 (91.0) |
369/401 (92.0) |
| Week 96 |
117/124 (94.4) |
9/9 (100) |
242/263 (92.0) |
368/396 (92.9) |
| Week 108 |
119/125 (95.2) |
8/9 (88.9) |
247/260 (95.0) |
374/394 (94.9) |
| Week 120 |
112/121 (92.6) |
7/8 (87.5) |
235/258 (91.1) |
354/387 (91.5) |
| Week 132 |
115/121 (95.0) |
6/7 (85.7) |
238/252 (94.4) |
359/380 (94.5) |
| Week 144 |
115/121 (95.0) |
7/7 (100) |
238/250 (95.2) |
360/378 (95.2) |
| Last available visit |
121/130 (93.1) |
11/13 (84.6) |
261/276 (94.6) |
393/419 (93.8) |
Notes: FAS=full analysis set; IR=immediate release; LLOQ=lower level of quantification; NVP=nevirapine; XR=extended release.
aPatients who received NVP IR during the first 48 weeks, and then switched to NVP XR.
bPatients who remained on NVP IR after week 48.
cPatients who remained on NVP XR after week 48. |
